ArticleLa Radiologia medica2026
xsCT-based radiomics for adrenal incidentaloma characterization.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this retrospective monocentric study is to examine the role of radiomics in distinguishing benign and malignant adrenal incidentalomas (AIs) analyzing computed tomography (CT) images. MATERIAL AND
methodsWe retrospectively selected patients with clinical or histologic diagnosis of adrenal pathology studied in the period 2011-2025 with pre-operative or pre-diagnostic CT in our center. Two radiology residents and a radiologist with 10 years of experience delineated the volume of interest of the AI using 3D-slicer software. All 135 patients included in the analysis underwent segmentation of the non-contrast acquisition; among these, 115 were also segmented on the portal phase acquisition. Statistical analysis was performed by dividing patients into two groups: group 0, benign adrenal pathology (adenoma, myelolipoma, ganglioneuroma, pseudocyst); group 1, malignant adrenal pathology (pheochromocytoma, adrenal cortical carcinoma, metastasis, lymphoma).
results135 patients were included. On non-contrast acquisition, the logistic regression model LASSO selected three first-order features and two second-order features able to distinguish patients belonging to Group 0 or Group 1. The features selected were used to construct a radiomic model that showed excellent AUC/discrimination (AUC: 0.88-95% CI 0.83-0.94). For portal phase, the logistic regression model LASSO selected three first-order features and two second-order features able to distinguish Group 0 and Group 1. The features selected were used to construct a radiomic model that showed excellent AUC/discrimination (AUC: 0.84- 95% CI 0.77-0.91).
conclusionThe radiomic models developed from both non-contrast and portal CT phases were effective in differentiating benign from malignant AIs.
Indexed as
Identifiers
42753040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.